NCT05217667Phase 2Terminated

Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)

Study sponsor: Arrowhead Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-05-02Actual
Enrollment · participants18Actual
Source updated2026-06-12Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Percent Change from Baseline in Fasting Calculated Low-Density Lipoprotein-Cholesterol (LDL-C) and LDL-C by Preparative Ultracentrifugation (LDL-C [PUC]) up to Week 24. After: Measure: Percent Change From Baseline in Fasting LDL-C at Week 24.

Recruitment status changed

Before: Active not recruiting. After: Terminated.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview